المؤلفون: Zhu, Rui¹ (AUTHOR), Schoemaker, Rik² (AUTHOR), Gautier, Aurelie³ (AUTHOR), Tian, Xianbin⁴ (AUTHOR), Sim, Cheryl HooiMing¹ (AUTHOR), Omachi, Theodore A.¹ (AUTHOR), Joshi, Amita¹ (AUTHOR), Jin, Jin¹ (AUTHOR), Owen, Ryan¹ (AUTHOR) owen.ryan@gene.com

المصدر: British Journal of Clinical Pharmacology. Dec2024, Vol. 90 Issue 12, p3190-3200. 11p.

مصطلحات موضوعية: *MONTE Carlo method, *OMALIZUMAB, *BODY weight, *FORCED expiratory volume, *ASTHMA, *IMMUNOGLOBULIN E

المؤلفون: Soegiharto, R.¹ (AUTHOR) r.soegiharto@umcutrecht.nl, Alizadeh Aghdam, M.¹ (AUTHOR), Sørensen, J. A.² (AUTHOR), Lindonk, E.³ (AUTHOR), Bulut Demir, F.⁴ (AUTHOR), Mohammad Porras, N.⁵ (AUTHOR), Matsuo, Y.⁶ (AUTHOR), Kiefer, L.^7,8 (AUTHOR), Knulst, A. C.¹ (AUTHOR), Maurer, M.^7,8 (AUTHOR), Ritchie, C.⁹ (AUTHOR), Rudenko, M.¹⁰ (AUTHOR), Kocatürk, E.^7,11 (AUTHOR), Criado, R. F. J.¹² (AUTHOR), Gregoriou, S.¹³ (AUTHOR), Bobylev, T.¹⁴ (AUTHOR), Kleinheinz, A.¹⁴ (AUTHOR), Takahagi, S.⁶ (AUTHOR), Hide, M.^6,15 (AUTHOR), Giménez‐Arnau, A. M.⁵ (AUTHOR)

المصدر: Allergy. Oct2024, p1. 11p. 3 Illustrations.

مصطلحات موضوعية: *OMALIZUMAB, *DISEASE duration, *PATIENT safety, *REGRESSION analysis, *TREATMENT duration

المؤلفون: Cihanbeylerden, Melek¹ (AUTHOR), Tuncay, Gülseren¹ (AUTHOR), Kayıkçı, Hazal¹ (AUTHOR), Damadoglu, Ebru¹ (AUTHOR), Karakaya, Gül¹ (AUTHOR), Kalyoncu, Ali Fuat¹ (AUTHOR)

المصدر: International Archives of Allergy & Immunology. 2024, Vol. 185 Issue 10, p947-952. 6p.

مصطلحات موضوعية: *OMALIZUMAB, *RESPIRATORY diseases, *EOSINOPHILS, *ORAL drug administration, *CORTICOSTEROIDS

المصدر: A Randomized, Double Blind, Three-arm, Parallel Group, Single Dose Comparative PK, PD, Safety and Immunogenicity Study Comparing ADL-018 With US-licensed XOLAIR in Healthy Adult Subjects

المصدر: A Global, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib 25 mg b.i.d. in Comparison to Placebo With Omalizumab 300 mg Every 4 Weeks as Active Control Over 52 Weeks in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines and an Open-label 52-week Optional Extension to Assess Long-term Efficacy, Safety and Tolerability of Remibrutinib 25 mg b.i.d.

المصدر: A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases

المؤلفون: Regeneron Pharmaceuticals

المصدر: A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15.

المصدر: Regulatory Post-Marketing Surveillance (rPMS) of Xolair® (Xolair® 150mg Powder for Solution for Injection, Xolair® 150mg/1ml Liquid in Pre-filled Syringe, Xolair® 75mg/0.5ml Liquid in Pre-filled Syringe) for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

المصدر: A Real-world, Prospective, Multicenter Study of Safety and Effectiveness of Xolair® (Omalizumab) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Chinese Adolescents Inadequately Controlled With H1 Antihistamines

المؤلفون: Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc.

المصدر: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)
Sampson HA, Berin MC, Plaut M, Sicherer SH, Jones S, Burks AW, Lindblad R, Leung DYM, Wood RA. The Consortium for Food Allergy Research (CoFAR): The first generation. J Allergy Clin Immunol. 2019 Feb;143(2):486-493. doi: 10.1016/j.jaci.2018.12.989. Epub 2018 Dec 23.
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25.

المساهمون: Lili Zhi, Dr. Prof.

المصدر: Efficacy and Safety Evaluation of Omalizumab Combined With Standardized Allergen Specific Immunotherapy in Moderate to Severe Allergic Asthma

المصدر: A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Other URLs: https://www.clinicalstudydatarequest.com

المؤلفون: Branicka, Olga¹ (AUTHOR) o.branicka@gmail.com, Rymarczyk, Barbara¹ (AUTHOR), Gawlik, Radosław¹ (AUTHOR), Glück, Joanna¹ (AUTHOR)

المصدر: Journal of Clinical Medicine. Aug2024, Vol. 13 Issue 15, p4287. 11p.

مصطلحات موضوعية: *EOSINOPHILS, *OMALIZUMAB, *BASOPHILS, *AUTOANTIBODIES, *URTICARIA

المؤلفون: Keskinkaya, Zeynep¹ (AUTHOR), Kaya, Özge¹ (AUTHOR), Işık Mermutlu, Selda¹ (AUTHOR), Öğretmen, Zerrin¹ (AUTHOR)

المصدر: International Archives of Allergy & Immunology. 2024, Vol. 185 Issue 8, p786-793. 8p.

مصطلحات موضوعية: *OMALIZUMAB, *IMMUNOGLOBULIN E, *SUBSTANCE abuse relapse, *AUTOANTIBODIES, *TREATMENT effectiveness, *URTICARIA

المؤلفون: Zhang, Fan¹ (AUTHOR), Liao, Jiashun² (AUTHOR), Qian, Yuan² (AUTHOR), Niu, Xinyu² (AUTHOR), Wei, Jia¹ (AUTHOR), Li, Man¹ (AUTHOR), Guo, Duyi¹ (AUTHOR), Zhu, Peiqiu¹ (AUTHOR)

المصدر: International Archives of Allergy & Immunology. 2024, Vol. 185 Issue 7, p718-728. 10p.

مصطلحات موضوعية: *OMALIZUMAB, *URTICARIA, *ALLERGIC rhinitis, *CHINESE people, *SCIENTIFIC observation

المؤلفون: Bozek, Andrzej¹ (AUTHOR) andrzej.bozek@sum.edu.pl, Rogala, Barbara² (AUTHOR), Miodonska, Martyna¹ (AUTHOR), Canonica, Giorgio Walter³ (AUTHOR)

المصدر: Journal of Asthma. Jun2024, Vol. 61 Issue 6, p532-538. 7p.

مصطلحات موضوعية: *ALLERGY desensitization, *OMALIZUMAB, *HOUSE dust mites, *ASTHMA, *ASTHMATICS

المؤلفون: Sangana, Ramachandra¹ (AUTHOR) ramachandra.sangana@novartis.com, Xu, Yan² (AUTHOR), Shah, Bharti³ (AUTHOR), Tian, Xianbin³ (AUTHOR), Zack, Julia³ (AUTHOR), Shakeri‐Nejad, Kasra⁴ (AUTHOR), Kalluri, Sampath⁵ (AUTHOR), Jones, Ieuan⁴ (AUTHOR), Ligueros‐Saylan, Monica³ (AUTHOR), Taylor, Angel Fowler³ (AUTHOR), Jain, Devendra Kumar⁴ (AUTHOR), Scosyrev, Emil³ (AUTHOR), Uddin, Alkaz³ (AUTHOR), Laurent, Nathalie⁴ (AUTHOR), Paganoni, Paola³ (AUTHOR)

المصدر: Clinical Pharmacology in Drug Development. Jun2024, Vol. 13 Issue 6, p611-620. 10p.

مصطلحات موضوعية: *RANDOMIZED controlled trials, *OMALIZUMAB, *PATIENT compliance, *NASAL polyps, *SYRINGES

المؤلفون: Atayik, Emel¹ emelakinci@yahoo.com, Aytekin, Gokhan¹, Aydin, Isa², Omeroglu, Ethem³

المصدر: Iranian Journal of Allergy, Asthma & Immunology. Jun2024, Vol. 23 Issue 3, p245-256. 12p.

مصطلحات موضوعية: *NASAL polyps, *OMALIZUMAB, *FORCED expiratory volume, *ASTHMA, *SINUSITIS, *ASTHMATICS

المؤلفون: Zubiaga‐Fernandez, L.¹ (AUTHOR), Testera‐Montes, A.^1,2 (AUTHOR), Rondon, C.^1,2 (AUTHOR), Perez‐Sanchez, N.^1,2 (AUTHOR), Gomez‐Perez, F.^1,2 (AUTHOR), Vega‐Chicote, J. M.¹ (AUTHOR), Bartra, J.^2,3 (AUTHOR), Ferrer, M.^2,4 (AUTHOR), Eguiluz‐Gracia, I.^1,2 (AUTHOR) iboneguiluz@gmail.com, Torres, M. J.^1,2,5 (AUTHOR)

المصدر: Clinical & Experimental Allergy. Jun2024, Vol. 54 Issue 6, p402-411. 10p.

مصطلحات موضوعية: *OMALIZUMAB, *URTICARIA, *BIOMARKERS, *BLOOD testing, *BASOPHILS

المؤلفون: Maurer, Marcus^1,2,3 (AUTHOR) marcus.maurer@charite.de, Ensina, Luis Felipe^1,4,5 (AUTHOR), Gimenez-Arnau, Ana Maria⁶ (AUTHOR), Sussman, Gordon⁷ (AUTHOR), Hide, Michihiro^8,9 (AUTHOR), Saini, Sarbjit¹⁰ (AUTHOR), Grattan, Clive¹¹ (AUTHOR), Fomina, Daria^12,13 (AUTHOR), Rigopoulos, Dimitrios¹⁴ (AUTHOR), Berard, Frederic¹⁵ (AUTHOR), Canonica, Giorgio Walter^16,17 (AUTHOR), Rockmann, Heike¹⁸ (AUTHOR), Irani, Carla¹⁹ (AUTHOR), Szepietowski, Jacek C²⁰ (AUTHOR), Leflein, Jeffrey²¹ (AUTHOR), Bernstein, Jonathan A²² (AUTHOR), Peter, Jonny G^23,24 (AUTHOR), Kulthanan, Kanokvalai²⁵ (AUTHOR), Godse, Kiran²⁶ (AUTHOR), Ardusso, Ledit²⁷ (AUTHOR)

المصدر: Lancet. Jan2024, Vol. 403 Issue 10422, p147-159. 13p.

مصطلحات موضوعية: URTICARIA, OMALIZUMAB, TEENAGERS, ADULTS